• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

    2/14/24 4:15:31 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OVID alert in real time by email
    SC 13G/A 1 tm246100d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Amendment No. 5)

     

    Under the Securities Exchange Act of 1934

     

    OVID THERAPEUTICS INC.

    (Name of Issuer)

     

    COMMON STOCK, $0.001 PAR VALUE

    (Title of Class of Securities)

     

    690469101

    (CUSIP Number)

     

    DECEMBER 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 690469101       Page 2 of 4 Pages

     

     

    1.  

    Name of Reporting Persons

    Jeremy M. Levin

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐ (b) ☒

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

    United States of America

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5.  

    Sole Voting Power

    6,942,181 (1)

      6.  

    Shared Voting Power

    0

      7.  

    Sole Dispositive Power

    6,942,181 (1)

      8.  

    Shared Dispositive Power

    0

     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,942,181 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐

    11.  

    Percent of Class Represented by Amount in Row (9)

    9.4% (2)

    12.  

    Type of Reporting Person (See Instructions)

    IN

     

    (1) Consists of (i) 3,598,467 shares of the Issuer’s common stock held directly by the Reporting Person, (ii) 35,461 shares held by Divo Holdings, LLC, a limited liability company managed by the Reporting Person’s spouse, and (iii) 3,308,253 shares of common stock issuable upon the exercise of stock options within 60 days of December 31, 2023.

     

    (2) This percentage is calculated based upon 70,680,551 outstanding shares of the Issuer’s common stock, as reported in the Issuer’s Form 10-Q Quarterly Report (Commission File No. 001-38085) filed with the Securities and Exchange Commission on November 3, 2023.

     

     

     

    CUSIP No. 690469101       Page 3 of 4 Pages

     

    Item 1(a) Name of Issuer

    Ovid Therapeutics Inc.

     

    Item 1(b) Address of Issuer’s Principal Executive Offices

    441 Ninth Avenue, 14th Floor

    New York, New York 10001

     

    Item 2(a) Name of Person Filing

    Jeremy M. Levin

     

    Item 2(b) Address of Principal Business Office or, if none, Residence

    c/o Ovid Therapeutics Inc.

    441 Ninth Avenue, 14th Floor

    New York, New York 10001

     

    Item 2(c) Citizenship

    United States of America

     

    Item 2(d) Title of Class of Securities

    Common Stock, $0.001 par value

     

    Item 2(e) CUSIP Number

    690469101

     

    Item 3

    Not applicable.

     

    Item 4 Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1

     

    (a) Amount beneficially owned: See Row 9 of cover page for each Reporting Person
    (b) Percent of class: See Row 11 of cover page for each Reporting Person
    (c) Number of shares as to which the person has:
      (i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
      (ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
      (iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
      (iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

     

    Item 5 Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6 Ownership of More than Five Percent of Another Person

    Not applicable.

     

    Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

    Not applicable.

     

    Item 8 Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9 Notice of Dissolution of Group

    Not applicable.

     

    Item 10 Certification

    Not applicable. 

     

     

     

    CUSIP No. 690469101       Page 4 of 4 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024.

     

      By:

    /s/ Jeremy M. Levin

        Jeremy M. Levin

     

     

    Get the next $OVID alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OVID

    DatePrice TargetRatingAnalyst
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    12/21/2023$11.00Buy
    BTIG Research
    10/13/2023$8.00Outperform
    Oppenheimer
    8/25/2021$4.50 → $4.00Neutral
    Citigroup
    More analyst ratings

    $OVID
    SEC Filings

    See more
    • Ovid Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      6/25/25 8:22:25 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ovid Therapeutics Inc.

      DEFA14A - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/22/25 8:05:26 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Ovid Therapeutics Inc.

      DEF 14A - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/22/25 8:04:33 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

      NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a definitive agreement with Immedica Pharma AB (‘Immedica'), a leading global rare disease company, for the sale of its future royalties related to sales of ganaxolone outside of China. Under the terms of the agreement, Immedica will pay $7 million in cash to acquire 100% of the royalty rights held by Ovid, further strengthening Immedica's focus on ganaxolone by acquiring control of additional intellectual property rights.

      6/25/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

      NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberger will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30

      6/5/25 7:30:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

      Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-endCash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today

      5/13/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care